Abstract
OBJECTIVE--To devise assays to assess and follow the specific antibody response in patients treated with streptokinase for acute myocardial infarction. DESIGN--Venous blood samples were collected before treatment with streptokinase started and subsequently at regular intervals over one year. Specific IgG and subclass IgG1 were assessed by an enzyme linked immunosorbent assay. SETTING--Coronary care unit in a general hospital. PATIENTS--48 patients with acute myocardial infarction: 22 patients had venous blood samples taken at presentation only; serial blood samples were taken from 20 patients who then received thrombolytic therapy with streptokinase and six patients who were unsuitable for thrombolytic therapy. RESULTS--Titres of antibodies to streptokinase were low at presentation in 36 (75%) of the 48 patients. Serial measurements made in 20 patients showed the virtual disappearance of antibody within the first 24 hours. This was followed by a steady increase in the specific IgG1 titre, which peaked at day 14 before gradually declining. Values at one year remained significantly higher than baseline values. There was no evidence of an IgM response in the patients studied. CONCLUSION--Low titres of antibodies to streptokinase were widespread in the population. Antibody was consumed after treatment and the subsequent immunoglobulin rise suggested a secondary immune responses; the recently described neutralising capacity to streptokinase is probably related to this antibody.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alexopoulos D., Raine A. E., Cobbe S. M. Serum sickness complicating intravenous streptokinase therapy in acute myocardial infarction. Eur Heart J. 1984 Dec;5(12):1010–1012. doi: 10.1093/oxfordjournals.eurheartj.a061602. [DOI] [PubMed] [Google Scholar]
- FAHEY J. L., MCKELVEY E. M. QUANTITATIVE DETERMINATION OF SERUM IMMUNOGLOBULINS IN ANTIBODY-AGAR PLATES. J Immunol. 1965 Jan;94:84–90. [PubMed] [Google Scholar]
- FLETCHER A. P., SHERRY S., ALKJAERSIG N., SMYRNIOTIS F. E., JICK S. The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest. 1959 Jul;38(7):1111–1119. doi: 10.1172/JCI103887. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jalihal S., Morris G. K. Antistreptokinase titres after intravenous streptokinase. Lancet. 1990 Jan 27;335(8683):184–185. doi: 10.1016/0140-6736(90)90276-b. [DOI] [PubMed] [Google Scholar]
- Mancini G., Carbonara A. O., Heremans J. F. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 1965 Sep;2(3):235–254. doi: 10.1016/0019-2791(65)90004-2. [DOI] [PubMed] [Google Scholar]
- McGrath K. G., Zeffren B., Alexander J., Kaplan K., Patterson R. Allergic reactions to streptokinase consistent with anaphylactic or antigen-antibody complex-mediated damage. J Allergy Clin Immunol. 1985 Sep;76(3):453–457. doi: 10.1016/0091-6749(85)90726-2. [DOI] [PubMed] [Google Scholar]
- McGrath K., Patterson R. Immunology of streptokinase in human subjects. Clin Exp Immunol. 1985 Nov;62(2):421–426. [PMC free article] [PubMed] [Google Scholar]
- Stevens R., Dichek D., Keld B., Heiner D. IgG1 is the predominant subclass of in vivo- and in vitro- produced anti-tetanus toxoid antibodies and also serves as the membrane IgG molecule for delivering inhibitory signals to anti-tetanus toxoid antibody-producing B cells. J Clin Immunol. 1983 Jan;3(1):65–69. doi: 10.1007/BF00919140. [DOI] [PubMed] [Google Scholar]
- Voller A., Bidwell D. E., Bartlett A. Enzyme immunoassays in diagnostic medicine. Theory and practice. Bull World Health Organ. 1976;53(1):55–65. [PMC free article] [PubMed] [Google Scholar]